Companion diagnostics are a form of in-vitro diagnostics which provide data about the therapeutic reactions of patients for a particular treatment. Companion diagnostics market is still developing, and it is expected to reach a market value of $3.5 billion by 2020 from a market value of $1.1 billion in the year 2013, registering a CAGR of 20% during 2014-2020.
Companion diagnostics are in-vitro diagnostics that provide information about therapeutic responses of patients for a specific treatment. Companion diagnostics market is still nascent, and it is projected to reach $3.5 billion by 2020 from a base value of $1.1 billion in 2013, growing at a CAGR of 20% during 2014 to 2020. The global companion diagnostic market is segmented based on indication, technology and geography (North America, Europe, Asia Pacific and LAMEA). Read the Complete Report @ http://www.researchbeam.com/companion-diagnostic-technologies-market
A companion diagnostic is an in vitro medical device that provides information which is essential for the safe and effective use of a corresponding drug or biological product. This diagnostic test helps a health care professional to determine whether a particular therapeutic product is beneficial to patients and can outweigh any potential serious side effects or risks.
Rise in prominence of personalized medicine, surge in cases of adverse drug reactions, and advancements in technologies for diagnostic techniques drive the growth in the global companion diagnostics market.
Research Nester released a report titled “Companion Animal Diagnostics Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers detailed overview of the global companion animal diagnostics market in terms of market segmentation by technology, application, animal type, end-user and region.
The Global Companion Diagnostics Market is expected to witness growth at a CAGR of 12.84% during the forecast period 2022-2028. Request a Free Sample Report.
The Global Companion Animal Diagnostics Market study focuses major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. It provides information on trends and developments, and focuses on markets and materials, capacities and technologies, and on the changing structure.
As per Roche’s Personalized Healthcare Brochure, for every 10 patients with cancer treated, only an average of half will actually benefit from it. Read more: https://inkwoodresearch.com/companion-diagnostics-market-relevant-developments-overview/
Medical treatments are typically designed using uniform patterns, with patients with the same disease. Get more insights into the Companion Diagnostic market.
The global companion diagnostics market was valued at $2608 million in 2017 & is estimated to generate net revenue of approximately $11980 million by 2026, growing at a CAGR of 18.45%.
The global companion diagnostics market is anticipated to grow at a CAGR of 13.29%, and is estimated to reach $15441.90 million by 2030. Get Free Sample Report.
This report, from Stratview Research, studies the global clinical diagnostics market - companion diagnostics over the trend period of 2014 to 2017 and forecast period of 2018 to 2025.
The Global Companion Diagnostics Market size is expected to reach $6.5 billion by 2025, rising at a market growth of 19.9% CAGR during the forecast period. A companion diagnostics test is done to understand which patient can gain benefits from a specific drug or decide upon the kind of dosage that should be prescribed. All of this, on the basis of a patients clinical diagnosis, which offers required evidence for the successful and harmless utilization of an equivalent biological or drug product to treat the medical issue. These can also be referred to as medical instruments that help doctors in electing which dosage or treatment is sufficient for patients and suits to their necessity. Full Report: https://www.kbvresearch.com/companion-diagnostics-market/
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed.
According to the latest research report by IMARC Group, The global companion diagnostics market size reached US$ 5.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 11.7 Billion by 2027, exhibiting a growth rate (CAGR) of 14.78% during 2022-2027. More Info:- https://www.imarcgroup.com/companion-diagnostics-market
This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. See Full Report: http://goo.gl/daXMJ8
Stay up-to-date with latest Insights of Companion Diagnostic market research offered by Allied Market Research. Check how key trends and emerging drivers are shaping this industry growth.
Companion Diagnostics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Companion Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource.
Looking forward, the companion diagnostics market value is projected to reach a strong growth during the forecast period (2021-2026). More info:- https://www.imarcgroup.com/companion-diagnostics-market
The companion animal diagnostics marketwas valued at US$ 2,031.62 million in2019 and is projected to reach US$ 2,684.86 million by 2027; it is expected to grow at a CAGR of 4.1%from 2020to 2027.
The Companion Diagnostics Market deals with the development of tests to comprehend which patient can be profited from a specific medication or what dose ought to be recommended in light of a patient's clinical conclusion, which gives the confirmation of required effective and innocuous utilization of a proportional medication or natural item to treat the restorative condition. Such medicinal instruments, produced by companion diagnostic companies, guide specialists to choose which treatment and measurements ought to be given to patients and are customized to their needs.
The global companion diagnostics market is anticipated to grow at a CAGR of 13.29%, and is estimated to reach $15441.90 million by 2030. Get Free Sample Report.
The new Companion Animal Diagnostic Market report offers a comprehensive study of the present scenario of the market coupled with major market dynamic. Also, it highlights the in-depth market analysis with the latest trends, drivers and its segments with respect to regional and country. Further, this report profiles top key players of the companion animal diagnostic and analyze their market share, strategic development and other development across the globe.
The global companion diagnostics market is anticipated to grow at a CAGR of 13.29%, and is estimated to reach $15441.90 million by 2030. Get Free Sample Report.
Global Companion Diagnostics Information, by types (theranostics and monitoring tests) by Application (cancer diseases, cardiovascular, central nervous systems) by end users (hospital, research laboratories, medical institutes), by Technology - Forecast to 2022
Alfa Wassermann Diagnostic Technologies, LLC (AWDT) is the provider of medical diagnostic instrumentation and reagents to the medical community. It offers diagnostics equipment to the physician office and veterinary lab markets. The product portfolio of the company comprises ACE Axcel Clinical Chemistry System, ACE Alera Chemistry System, Alfa Laboratory Information System (LIS), Vet Alera Chemistry Analyzer and Vet LIS. It operates as the subsidiary of Alfa Wassermann, Inc. AWDT is headquartered in New Jersey, the US.
The report "Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026", the global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6%.
Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd, GE Healthcare Ltd., and Thermo Fisher Scientific....@ @ https://bit.ly/3hjIN2n
A nurse call system is a nursing management and communication system that uses IP technology, which can be used for both wired and wireless connections. The features of the nurse call system make it perfect for use in hospitals, clinics, day centers, and others. The global nurse call systems market is valued at US$ 1.03 billion in 2018 and is expected to grow at a CAGR of 9.2% during the forecast period
The Global Companion Diagnostics Market is expected to witness growth at a CAGR of 12.84% during the forecast period 2022-2028. Request a Free Sample Report.
Aarkstore.com is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service
This report covers market size and forecasts of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx), including the following market information: Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)
A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy.
A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to a disease condition or therapy.
Similar to humans, animals too suffer from chronic diseases. Arthritis and other orthopedic conditions, chronic kidney disease, cancer, hepatitis and other liver diseases, skin allergies, diabetes mellitus, inflammatory bowel disease, and thyroid disorders are among the common chronic diseases in pets. Cancer is widespread in animals and affects pet as well as wild animals. Animals have been diagnosed with various types of cancer till date, which have symptoms similar to humans, including weight loss, abnormal swelling,
Increase in burden of cancer globally, growing demand for personalized medicine and targeted therapy coupled with increase in adoption of drug diagnostics co-development model by industry players are the key factors driving the global companion diagnostics market.
“Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment” is a cutting-edge comprehensive report on the personalized medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, companion diagnostics and the associated market environment. See Full Report : http://bit.ly/1xTcMmO
BioMarCare Technologies Ltd. (BioMarCare Technologies) is a cancer diagnostics company. BioMarCare Technologies develops tumor biomarkers for diagnosis, prognosis, monitoring, surveillance, screening and companion diagnostics. The company develops a range of diagnostic and prognostic tests for the common types of cancer including mCRC-Strat, PARpanel and MarCare. Currently, the company seeks a strategic alliance and investment funds of around $ 3m for product development and clinical studies. The company is headquartered in Jerusalem, Israel.
Bharat Book Bureau provides the report, on "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment”. https://www.bharatbook.com/healthcare-market-research-reports-433355/personalized-medicine-targeted-therapeutics-companion-diagnostic.html This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments.
Market Overview: Cancer Tissue Diagnostics Market Cancer tissue diagnostics play a pivotal role in oncology by facilitating accurate diagnosis, prognosis, and treatment selection based on tissue samples obtained from patients. The global cancer tissue diagnostics market is witnessing steady growth, driven by the increasing incidence of cancer, advancements in diagnostic technologies, and growing emphasis on personalized medicine.
The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3136.9 million in 2014, at a CAGR of 22.7% during the forecast period (2014 to 2019).
The Global Cancer Diagnostics Partnering Market Report contains over 1,000 links to online copies of actual cancer diagnostics deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The Global Cancer Diagnostics Partnering Market Report contains over 1,000 links to online copies of actual cancer diagnostics deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Global Diagnostics Partnering Market 2010-2015 report covers the key players in this industry and over 3000 global deals. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.